We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

85 hedge funds and large institutions have $522M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 36 increasing their positions, 17 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

112% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 17

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

6% more funds holding

Funds holding: 8085 (+5)

0% more capital invested

Capital invested by funds: $522M → $522M (+$40.5K)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

96% less call options, than puts

Call options by funds: $778K | Put options by funds: $20.5M

Holders
85
Holders Change
+5
Holders Change %
+6.25%
% of All Funds
1.85%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.07%
New
18
Increased
36
Reduced
17
Closed
11
Calls
$778K
Puts
$20.5M
Net Calls
-$19.7M
Net Calls Change
-$19.7M
Name Holding Trade Value Shares
Change
Change in
Stake
NLVP
1
New Leaf Venture Partners
New York
$92.5M
O
2
OrbiMed
New York
$81.6M
RG
3
Redmile Group
California
$50.1M +$13.9M +594,723 +37%
BlackRock
4
BlackRock
New York
$34.5M +$7.3M +311,870 +26%
Millennium Management
5
Millennium Management
New York
$33M +$4.84M +206,868 +16%
SHI
6
SV Health Investors
Massachusetts
$20.7M -$7.49M -319,861 -26%
Vanguard Group
7
Vanguard Group
Pennsylvania
$17.9M +$474K +20,252 +3%
Janus Henderson Group
8
Janus Henderson Group
United Kingdom
$15.2M +$328K +14,028 +2%
Alkeon Capital Management
9
Alkeon Capital Management
New York
$14.7M
State Street
10
State Street
Massachusetts
$14.2M +$178K +7,610 +1%
DM
11
Deerfield Management
New York
$13.7M
ACH
12
ArrowMark Colorado Holdings
Colorado
$12.3M +$3.52M +150,365 +38%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$10.8M +$2.27M +97,009 +26%
EA
14
Emerald Advisers
Pennsylvania
$8.98M -$108K -4,613 -1%
EMFAT
15
Emerald Mutual Fund Advisers Trust
Pennsylvania
$8.21M
Lord, Abbett & Co
16
Lord, Abbett & Co
New Jersey
$7.99M +$1.09M +46,371 +15%
OM
17
Opaleye Management
Massachusetts
$6.99M -$702K -30,000 -9%
EP
18
Eversept Partners
New York
$6.88M +$1.28M +54,801 +22%
KCM
19
Kingdon Capital Management
New York
$6.68M +$2.61M +111,352 +60%
Citadel Advisors
20
Citadel Advisors
Florida
$6.52M -$1.78M -76,019 -21%
Hudson Bay Capital Management
21
Hudson Bay Capital Management
Connecticut
$5.53M +$2.66M +113,705 +87%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$4.89M +$821K +35,061 +19%
KCM
23
Kornitzer Capital Management
Kansas
$4.8M -$20.4K -870 -0.4%
Point72 Asset Management
24
Point72 Asset Management
Connecticut
$4.61M +$4.78M +204,274 New
Alyeska Investment Group
25
Alyeska Investment Group
Illinois
$3.14M +$2.01M +85,910 +161%

DCPH Hedge Fund Activity: Q2 2019 in Review

85 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q2 2019, worth a combined $522M — up 0.01% from $522M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new DCPH positions and 11 closed out — a net gain of 7 holders — while 36 added to existing stakes and 17 trimmed.

The largest buyer was Redmile Group, adding an estimated $13.9M. The largest seller was AllianceBernstein, cutting an estimated $11.6M.

  • 85 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q2 2019, up from 80 in Q1 2019.
  • Funds reported $522M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q2 2019, up 0.01% quarter-over-quarter.
  • 18 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q2 2019 and 11 closed out, a net change of +7 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q2 2019 was Redmile Group, an estimated $13.9M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q2 2019 was AllianceBernstein, an estimated $11.6M sold.

Based on aggregated 13F filings for Q2 2019.